These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 33798735)
21. Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. Murray S; Briasoulis E; Linardou H; Bafaloukos D; Papadimitriou C Cancer Treat Rev; 2012 Nov; 38(7):890-903. PubMed ID: 22465195 [TBL] [Abstract][Full Text] [Related]
22. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials. Sparano JA Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388 [TBL] [Abstract][Full Text] [Related]
23. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions. Goble S; Bear HD Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604 [TBL] [Abstract][Full Text] [Related]
24. Clinical benefit of switching from paclitaxel to docetaxel or vice versa in cutaneous angiosarcoma patients resistant to first taxane chemotherapy. Yonekura S; Endo Y; Fujii H; Ishikawa M; Egawa G; Kabashima K J Dermatol; 2023 Nov; 50(11):1493-1496. PubMed ID: 37400887 [TBL] [Abstract][Full Text] [Related]
25. Taxanes in cancer treatment: Activity, chemoresistance and its overcoming. Mosca L; Ilari A; Fazi F; Assaraf YG; Colotti G Drug Resist Updat; 2021 Jan; 54():100742. PubMed ID: 33429249 [TBL] [Abstract][Full Text] [Related]
26. Docetaxel: an alternative taxane in ovarian cancer. Katsumata N Br J Cancer; 2003 Dec; 89 Suppl 3(Suppl 3):S9-S15. PubMed ID: 14661041 [TBL] [Abstract][Full Text] [Related]
27. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Rouzier R; Rajan R; Wagner P; Hess KR; Gold DL; Stec J; Ayers M; Ross JS; Zhang P; Buchholz TA; Kuerer H; Green M; Arun B; Hortobagyi GN; Symmans WF; Pusztai L Proc Natl Acad Sci U S A; 2005 Jun; 102(23):8315-20. PubMed ID: 15914550 [TBL] [Abstract][Full Text] [Related]
28. Influence of microtubule-associated proteins on the differential effects of paclitaxel and docetaxel. Fromes Y; Gounon P; Veitia R; Bissery MC; Fellous A J Protein Chem; 1996 May; 15(4):377-88. PubMed ID: 8819014 [TBL] [Abstract][Full Text] [Related]
29. Structural insight into the stabilization of microtubules by taxanes. Prota AE; Lucena-Agell D; Ma Y; Estevez-Gallego J; Li S; Bargsten K; Josa-Prado F; Altmann KH; Gaillard N; Kamimura S; Mühlethaler T; Gago F; Oliva MA; Steinmetz MO; Fang WS; Díaz JF Elife; 2023 Mar; 12():. PubMed ID: 36876916 [TBL] [Abstract][Full Text] [Related]
30. Clinical overview of the taxanes. Goldspiel BR Pharmacotherapy; 1997; 17(5 Pt 2):110S-125S. PubMed ID: 9322878 [TBL] [Abstract][Full Text] [Related]
31. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Andre F; Hatzis C; Anderson K; Sotiriou C; Mazouni C; Mejia J; Wang B; Hortobagyi GN; Symmans WF; Pusztai L Clin Cancer Res; 2007 Apr; 13(7):2061-7. PubMed ID: 17404087 [TBL] [Abstract][Full Text] [Related]
32. Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells. Souchek JJ; Davis AL; Hill TK; Holmes MB; Qi B; Singh PK; Kridel SJ; Mohs AM Mol Cancer Ther; 2017 Sep; 16(9):1819-1830. PubMed ID: 28615298 [TBL] [Abstract][Full Text] [Related]
33. Predictive value of microtubule-associated protein Tau in patients with recurrent and metastatic breast cancer treated with taxane-containing palliative chemotherapy. Zhou J; Qian S; Li H; He W; Tan X; Zhang Q; Han G; Chen G; Luo R Tumour Biol; 2015 May; 36(5):3941-7. PubMed ID: 25773385 [TBL] [Abstract][Full Text] [Related]
34. Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial. Nomura H; Aoki D; Michimae H; Mizuno M; Nakai H; Arai M; Sasagawa M; Ushijima K; Sugiyama T; Saito M; Tokunaga H; Matoda M; Nakanishi T; Watanabe Y; Takahashi F; Saito T; Yaegashi N; JAMA Oncol; 2019 Jun; 5(6):833-840. PubMed ID: 30896757 [TBL] [Abstract][Full Text] [Related]
35. Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial. Takashima T; Mukai H; Hara F; Matsubara N; Saito T; Takano T; Park Y; Toyama T; Hozumi Y; Tsurutani J; Imoto S; Watanabe T; Sagara Y; Nishimura R; Shimozuma K; Ohashi Y; Lancet Oncol; 2016 Jan; 17(1):90-8. PubMed ID: 26617202 [TBL] [Abstract][Full Text] [Related]
36. The Evolving and Future Role of Taxanes in Squamous Cell Carcinomas of the Head and Neck: A Review. Mody MD; Gill HS; Saba NF JAMA Otolaryngol Head Neck Surg; 2016 Sep; 142(9):898-905. PubMed ID: 27389786 [TBL] [Abstract][Full Text] [Related]
37. Taxanes for adjuvant treatment of early breast cancer. Ferguson T; Wilcken N; Vagg R; Ghersi D; Nowak AK Cochrane Database Syst Rev; 2007 Oct; (4):CD004421. PubMed ID: 17943815 [TBL] [Abstract][Full Text] [Related]
38. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer. Martin SK; Kyprianou N Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899 [TBL] [Abstract][Full Text] [Related]
39. Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. Pusztai L Ann Oncol; 2007 Dec; 18 Suppl 12():xii15-20. PubMed ID: 18083698 [TBL] [Abstract][Full Text] [Related]
40. The Effect of Tau and Taxol on Polymerization of MCF7 Microtubules In Vitro. Feizabadi MS; Castillon VJ Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054875 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]